GUIAS HIPERTENSION ARTERIAL.indb - Scc

278
GUÍAS COLOMBIANAS PARA EL DIAGNÓSTICO
Y TRATAMIENTO DE LA HIPERTENSIÓN ARTERIAL
21. Ruggenenti P, Perna A, Gherardi G, et al. Renoprotective properties of ACEinhibition
in non diabetic nephropathies with non nephritic proteinuria. Lancet
1999; 354: 359-364.
22. Giatras I, Lau J, Levey As. Effect of angiotensin-converting enzyme inhibitors on
the progression of nondiabetic renal disease: a metaanalysis of randomized
trials. Angiotensin-Converting-Enzyme Inhibition and Progressive Renal Disease
Study Group. Ann Intern Med 1997; 127: 337-345.
23. Agodoa LY, Appel L, Bakris GL, et al. African American Study of Kidney Disease
and Hypertension (AASK) Study Group. Effect of ramipril vs. amlodipine on renal
outcomes in hypertensive nephrosclerosis: A randomized controlled trial. JAMA
2001; 285: 2719-2728.
24. Wright JT Jr, Bakris GL, Greene T, et al. Effect of blood pressure lowering and
antihypertensive drug class on progression of hypertensive kidney disease: results
from the AASK trial. JAMA 2002; 288: 2421-2431.
25. Levey A. Nondiabetic kidney disease. N Engl J Med 2002; 347: 1505-1511.
26. Mangrum AJ, Bakris GL. Angiotensin-converting enzyme inhibitors and angiotensin
receptor blockers in chronic renal disease: safety issues. Semin Nephrol
2004; 24: 168-175.
27. Nakao N, Yoshimura A, Morita H, et al. Combination treatment of angiotensin
II receptor blocker and angiotensin-converting-enzime inhibitor in non-diabetic
renal disease (COOPERATE): a randomised controlled trial. Lancet 2003; 361:
117-124.
28. Gashti CN, Bakris GL. The role of calcium antagonists in chronic kidney disease.
Curr Opin Nephrol Hypertens 2004; 13: 155-161.
29. De Leeuw PW, Ruilope LM, Palmer CR, et al. Clinical significance of renal
function in hypertensive patients at high risk. Results from the INSIGHT trial.
Arch Intern Med 2004; 164: 2459-2464.
Revista Colombiana de Cardiología
Febrero 2007
30. Contreras G, Greene T, Agodoa LY, et al. Blood pressure control, drug therapy,
and kidney disease. Hypertension 2005; 46: 44-50.
31. Sarnak MJ, Greene T, Wang X, et al. The effect of a lower target blood pressure
on the progression of kidney disease: long-term follow–up of the Modification
of Diet in Renal Disease Study. Ann Intern Med 2005; 142: 342-351.
32. Ruggenenti P, Perna A, Loriga G, et al. Blood pressure control for renoprotection
in patients with non-diabetic chronic renal disease (REIN-2): multicentre
randomised controlled trial. Lancet 2005; 365: 939-946.
33. Boero R, Rollini C, Massara C. The Verapamil versus Amlodipine in nondiabetic
nephropathies treated with trandolapril study. Am J Kidney Dis 2003; 42: 67-75.
34. Robles NR, Ojon J, Gómez CF, et al. Lercanidipine in patients with chronic renal
failure: The ZAFRA Study. Ren Fail 2005; 27: 73-80.
35. Klag MJ, Whelton PK, Randall PL, et al. Blood pressure and end-stage renal
disease in men. N Engl J Med 1996; 334: 13-18.
36. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine.
Nephron 1976; 16: 31-41.
37. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate
method to estimate glomerular filtration rate from serum creatinine: a new
prediction equation. Modification of Diet in Renal Disease Study Group. Ann
Intern Med 1999; 130: 461-470.
38. Levey AS, Greene T, Kusek J, Beck G. A simplified equation to predict glomerular filtration
rate from serum creatinine (abstract). J Am Soc Nephrol 2000; 11: 155A.
39. Levey AS, Coresh J, Balk E, et al. National Kidney Foundation practice guidelines
for chronic kidney disease: evaluation, classification, and stratification. Ann Intern
Med 2003; 139: 137-147.